BRPI1016133A2 - vacina, método para dispensar um antígeno a um mamífero, composição, métodos para dispensar sirna dentro de células que apresentam antígeno profissionais, para inibir a proliferação de células de tumor, e para dispensar um ácido nucleico a uma célula. - Google Patents

vacina, método para dispensar um antígeno a um mamífero, composição, métodos para dispensar sirna dentro de células que apresentam antígeno profissionais, para inibir a proliferação de células de tumor, e para dispensar um ácido nucleico a uma célula.

Info

Publication number
BRPI1016133A2
BRPI1016133A2 BRPI1016133A BRPI1016133A BRPI1016133A2 BR PI1016133 A2 BRPI1016133 A2 BR PI1016133A2 BR PI1016133 A BRPI1016133 A BR PI1016133A BR PI1016133 A BRPI1016133 A BR PI1016133A BR PI1016133 A2 BRPI1016133 A2 BR PI1016133A2
Authority
BR
Brazil
Prior art keywords
dispensing
siren
vaccine
mammal
cell
Prior art date
Application number
BRPI1016133A
Other languages
English (en)
Inventor
Angel Kaifer
Bonnie Beth Blomberg
Paolo Serafini
Pirouz Mohammad Daftarian
Vance Paul Lemmon
Victor L Perez
Wei Li
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of BRPI1016133A2 publication Critical patent/BRPI1016133A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/005—Hyperbranched macromolecules
    • C08G83/006—After treatment of hyperbranched macromolecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1016133A 2009-04-01 2010-04-01 vacina, método para dispensar um antígeno a um mamífero, composição, métodos para dispensar sirna dentro de células que apresentam antígeno profissionais, para inibir a proliferação de células de tumor, e para dispensar um ácido nucleico a uma célula. BRPI1016133A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16573209P 2009-04-01 2009-04-01
PCT/US2010/029694 WO2010115046A2 (en) 2009-04-01 2010-04-01 Vaccine compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI1016133A2 true BRPI1016133A2 (pt) 2016-04-19

Family

ID=42828943

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1016133A BRPI1016133A2 (pt) 2009-04-01 2010-04-01 vacina, método para dispensar um antígeno a um mamífero, composição, métodos para dispensar sirna dentro de células que apresentam antígeno profissionais, para inibir a proliferação de células de tumor, e para dispensar um ácido nucleico a uma célula.

Country Status (9)

Country Link
US (2) US9764012B2 (pt)
EP (1) EP2413964B1 (pt)
JP (4) JP5661735B2 (pt)
CN (2) CN102448491A (pt)
AU (1) AU2010232512B2 (pt)
BR (1) BRPI1016133A2 (pt)
CA (1) CA2756996C (pt)
RU (2) RU2600798C2 (pt)
WO (1) WO2010115046A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657480T3 (es) 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
WO2009101205A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
AU2010232512B2 (en) 2009-04-01 2013-07-18 University Of Miami Vaccine compositions and methods of use thereof
EP3611270B1 (en) * 2009-05-19 2021-12-01 University Of Miami Kits for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
CN102481376B (zh) 2009-05-27 2016-12-21 西莱克塔生物科技公司 免疫调节剂-聚合物化合物
US20110293723A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
EA201490520A1 (ru) * 2011-09-07 2014-09-30 Мидатек Лимитед Противоопухолевые вакцины на основе наночастиц
ES2627507T3 (es) * 2011-09-07 2017-07-28 Midatech Ltd. Composiciones de nanopartícula-péptido
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
WO2014120804A1 (en) * 2013-01-30 2014-08-07 University Of Miami Enteric coated nanoparticles for oral vaccine and drug delivery and methods of production and use thereof
IN2014CH00390A (pt) * 2013-02-05 2015-07-31 Nitto Denko Corp
US20140220079A1 (en) * 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for mucosal administration
EP2972363B1 (en) * 2013-03-15 2019-10-09 University Of Miami Immune-potentiating drug nanocarriers
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
EP3038609B1 (en) * 2013-08-27 2021-07-28 Deutsches Krebsforschungszentrum Cytotoxic t cell response modifiers
EP3906939A1 (en) * 2013-10-11 2021-11-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
WO2015116568A2 (en) * 2014-01-28 2015-08-06 University Of Miami Muscle cell-targeting nanoparticles for vaccination and nucleic acid delivery, and methods of production and use thereof
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
AU2016326695B2 (en) * 2015-09-23 2019-11-28 Massachusetts Institute Of Technology Compositions and methods for modified dendrimer nanoparticle vaccine delivery
JP6925688B2 (ja) 2015-10-22 2021-08-25 モデルナティーエックス， インコーポレイテッド 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
JP2018531290A (ja) 2015-10-22 2018-10-25 モデルナティーエックス， インコーポレイテッド 性感染症ワクチン
CA3024705A1 (en) * 2016-05-23 2017-11-30 University Of Miami Compositions for selective humoral responses and methods of use thereof
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018151816A1 (en) * 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
EP3424524B1 (en) * 2017-07-04 2024-12-11 CureVac SE Cancer rna-vaccine
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
ES3021410T3 (en) 2018-01-28 2025-05-26 Enable Biosciences Inc Reagents and methods for blocking non-specific interactions with nucleic acids
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
CN110448695B (zh) * 2019-08-23 2021-07-27 中山大学肿瘤防治中心 一种mRNA疫苗递送载体及其制备方法
EP4308165A1 (en) * 2021-03-17 2024-01-24 Northwestern University Dendritic peptide conjugated polymers for efficient intracellular delivery of nucleic acids to immune cells
CN113173985A (zh) * 2021-03-24 2021-07-27 深圳市新靶向生物科技有限公司 一种与结直肠癌驱动基因突变相关的抗原肽及其应用
CN120209073B (zh) * 2025-05-28 2025-09-23 北京立康生命科技有限公司 一种有利于抗原呈递的间隔肽

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
US3023A (en) * 1843-03-30 peters
US20050169900A1 (en) 1993-02-17 2005-08-04 Sloan Kettering Institute For Cancer Research Allogeneic vaccine and methods to synthesize same
US6864060B1 (en) * 1993-03-31 2005-03-08 Cadus Technologies, Inc. Yeast cells expressing modified G proteins and methods of use therefor
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
CA2184132C (en) 1995-09-21 2011-03-15 Kristina J. Hennessy An adjuvanted vaccine which is substantially free of non-host albumin
US6204250B1 (en) * 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
DE69834808T2 (de) 1997-03-27 2007-06-06 Institut Pasteur Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung
AU9031798A (en) * 1997-08-22 1999-03-16 Richard C. Morlock Sensor housing for uv curing chamber
CZ20011049A3 (cs) 1998-10-05 2002-08-14 Pharmexa A/S Imunogenní kompozice a způsob selekce imunogenního analogu
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US20040241842A1 (en) 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US6632435B1 (en) 1999-10-20 2003-10-14 City Of Hope CTL epitope analogs
CA2393730A1 (en) * 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
CA2349506C (en) 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
US20060035291A1 (en) 2001-09-18 2006-02-16 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
EP1448598A2 (en) 2001-11-16 2004-08-25 Pharmexa A/S Novel immunogenic mimetics of multimer proteins
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
AU2003208314A1 (en) 2002-03-11 2003-09-22 Pharmexa A/S Novel application of vaccination against tnf-alpha
US20080268457A1 (en) 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
CN1809379A (zh) 2003-04-18 2006-07-26 诺伍德免疫学有限公司 先于胸腺再活化的疾病预防和疫苗接种
CN101506266A (zh) 2005-02-01 2009-08-12 梅迪沃什有限公司 疫苗输送组合物及使用方法
US7358231B1 (en) 2005-12-01 2008-04-15 Applera Corporation Pancreatic cancer secreted targets and uses thereof
US8954355B2 (en) * 2006-01-26 2015-02-10 Psi Systems, Inc. Integrated postage and shipping label system
WO2007089607A2 (en) 2006-01-26 2007-08-09 University Of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
WO2008054540A2 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2132569B1 (en) 2007-03-16 2015-10-28 Cellestis Limited A cell-mediated immune response assay and kits therefor
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
CN102317303A (zh) * 2007-07-31 2012-01-11 约翰·霍普金斯大学 用于肿瘤或感染性疾病的免疫预防或免疫治疗的多肽-核酸偶联物
AU2010232512B2 (en) 2009-04-01 2013-07-18 University Of Miami Vaccine compositions and methods of use thereof

Also Published As

Publication number Publication date
JP2015096520A (ja) 2015-05-21
JP2012522802A (ja) 2012-09-27
WO2010115046A3 (en) 2010-11-25
US20120093761A1 (en) 2012-04-19
CN107050440A (zh) 2017-08-18
RU2016137258A (ru) 2018-12-13
EP2413964A4 (en) 2013-12-25
CA2756996A1 (en) 2010-10-07
US9764012B2 (en) 2017-09-19
EP2413964A2 (en) 2012-02-08
JP2017165755A (ja) 2017-09-21
RU2600798C2 (ru) 2016-10-27
WO2010115046A2 (en) 2010-10-07
CN102448491A (zh) 2012-05-09
US20180099032A1 (en) 2018-04-12
EP2413964B1 (en) 2019-11-13
JP6321261B2 (ja) 2018-05-09
CA2756996C (en) 2018-12-11
JP6139000B2 (ja) 2017-05-31
AU2010232512A1 (en) 2011-10-27
AU2010232512B2 (en) 2013-07-18
RU2011144089A (ru) 2013-05-10
RU2016137258A3 (pt) 2020-02-19
CN107050440B (zh) 2021-10-29
JP2016188222A (ja) 2016-11-04
JP5661735B2 (ja) 2015-01-28
AU2010232512A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
BRPI1016133A2 (pt) vacina, método para dispensar um antígeno a um mamífero, composição, métodos para dispensar sirna dentro de células que apresentam antígeno profissionais, para inibir a proliferação de células de tumor, e para dispensar um ácido nucleico a uma célula.
IL288241A (en) Improved methods of cell culture for adoptive cell therapy
IL273159A (en) A culture medium preparation, and a method for culturing cells or tissues by using the preparation
IL271005A (en) Improved methods of cell culture for adoptive cell therapy
HRP20171823T1 (hr) Postupak izdvajanja nukleinskih kiselina i komplet u tu svrhu
BR112014000341A2 (pt) proteína de ligação ao antígeno, método para tratamento de um paciente com uma doença, uso de uma proteína de ligação ao antígeno, ácido nucleico, e, célula hospedeira
GB2487632B (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
HUE038850T2 (hu) Eljárások és kompozíciók cél-DNS RNS-irányított módosításához és transzkripció RNS-irányított modulálásához
BR112013014527A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
ZA201403601B (en) Systems and methods for engineering nucleic acid constructs using scoring techniques
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
AR092487A2 (es) Anticuerpos contra la angiopoyetina 2 humana
ES2674239T8 (es) Medios para células madre pluripotentes carentes de alimentadores que contienen suero humano
BRPI0906795A2 (pt) Método para produzir um l-aminoácido
BRPI0918299A2 (pt) Método para produzir um l-aminoácido
HUE036910T2 (hu) Eljárás alaptápközeg elõállítására kötõszöveti õssejtekhez, alaptápközeg kötõszöveti õssejtekhez és annak tenyésztésével és differenciálásával történõ alkalmazásával elõállított sejtterápiás szer
IL228971A0 (en) Preparations and methods for the detection and identification of nucleic acid sequences in biological samples
BR112012032172A2 (pt) método para produzir um álcool e composição
ZA201302644B (en) Method for producing acrylic acid from ethanol and formaldehyde
BR112014013956A8 (pt) aparelho, sistema e método para identificar células tumorais circulantes
BR112013015215A2 (pt) métodos e aparelhos para recuperação aperfeiçoada de células e de matrix enriquecida por células a partir de amostras de tecido
AR079704A1 (es) Anticuerpos anti-bv8 y sus usos
BRPI0912755A2 (pt) Método para produzir um l-aminoácido
BR112013004044A2 (pt) composições e métodos para quantificação de uma sequência de ácido nucleico em uma amostra.
BR112014003431A2 (pt) anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL